The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The POWER1 study evaluating the efficacy of vormatrigine in patients with focal onset seizures failed to meet its primary success measure. As a result, Praxis has paused enrollment in the POWER2 study to reassess the vormatrigine program and determine potential modifications. However, higher doses (30 mg) showed a more pronounced reduction in seizures, and the drug was generally well-tolerated.